Sylentis Preps to Move Glaucoma Drug into Phase II Next Year | GenomeWeb

This article has been updated to correct details regarding SYL1001's development timeline.

Spanish RNAi drug developer Sylentis is gearing up to begin a phase II trial of its investigational glaucoma treatment SYL040012, which could start as soon as by the end of the year, Gene Silencing News has learned.

At the same time, the company plans to begin a second phase I trial of an RNAi-based treatment for dry eye-associated pain, called SYL1001, later this year, according to a Sylentis spokeswoman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.